Beam Therapeutics FCF yield
What is the FCF yield of Beam Therapeutics?
The FCF yield of Beam Therapeutics Inc. is -4.85%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with fcf yield similar to Beam Therapeutics
- Scully Royalty Ltd has FCF yield of -4.88%
- TDK has FCF yield of -4.88%
- Sarepta Therapeutics Inc has FCF yield of -4.88%
- Calix has FCF yield of -4.88%
- Tyro Payments has FCF yield of -4.87%
- SNP Schneider-Neureither & Partner SE has FCF yield of -4.87%
- Beam Therapeutics has FCF yield of -4.85%
- Manitowoc Co has FCF yield of -4.85%
- Lightspeed POS has FCF yield of -4.84%
- Lachlan Star has FCF yield of -4.84%
- Seb Sa has FCF yield of -4.84%
- Ponsse Oyj has FCF yield of -4.83%
- cbdMD Inc has FCF yield of -4.82%